HER2+ BC, in which the cells do not express estrogen receptors and progesterone receptors, accounts for about 15% of all BC cases and presents a high rate of recurrence and poor prognosis compared with hormone-receptor-positive BC [7,8,9]. Here, ERBB2 is linked to breast cancer.